Immunotherapy & Chemo: 50% Lower Recurrence in Stage 3 Colon Cancer with dMMR
The news coming out of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago is a significant one, particularly for those of us following advancements in colorectal cancer treatment. While colon cancer remains the third most prevalent cancer in the United States, and alarmingly, is increasing among younger adults, a latest study led by the Mayo Clinic offers a beacon of hope. The research demonstrates that adding immunotherapy to the standard chemotherapy regimen after surgery for stage 3 colon cancer—specifically in patients with deficient DNA mismatch repair (dMMR)—can reduce cancer recurrence and mortality by a remarkable 50%. This isn’t just incremental progress; it’s a potential paradigm shift, and one that deserves close attention here in Austin, Texas.
Understanding the dMMR Factor and the Promise of Immunotherapy
Approximately 15% of colorectal cancer diagnoses involve this dMMR genetic makeup. Historically, these tumors haven’t responded as effectively to traditional chemotherapy, creating a frustrating challenge for oncologists. The Mayo Clinic study, published in the New England Journal of Medicine, changes that narrative. The key lies in immunotherapy, specifically an immune checkpoint inhibitor called atezolizumab. This isn’t about directly attacking the cancer cells; it’s about unleashing the patient’s own immune system to recognize and destroy them. Atezolizumab essentially removes the “brakes” on the immune response, allowing it to target and eliminate cancer cells responsible for recurrence and spread.
The clinical trial, involving 712 patients from both the U.S. And Germany, randomized participants to receive either chemotherapy plus immunotherapy (immunotherapy continued alone for six months after chemo) or chemotherapy alone. The results were compelling. This isn’t just theoretical; it’s a tangible improvement in outcomes, and it’s particularly relevant as we see rising rates of colorectal cancer in younger adults – a trend that’s been noted nationally, and is certainly something local physicians at institutions like the Dell Medical School at the University of Texas at Austin are monitoring closely.
Why This Matters in Austin, Texas
Austin, with its rapidly growing and relatively young population, is a city increasingly focused on preventative health and access to cutting-edge medical care. The implications of this research extend beyond the individual patient. The rising incidence of colorectal cancer in younger adults necessitates a proactive approach to screening and treatment. The fact that this new treatment protocol specifically targets a genetic marker – dMMR – means that genetic testing will become even more crucial in guiding treatment decisions. Local facilities like St. David’s Medical Center and Ascension Seton Medical Center will likely be adapting their protocols to incorporate this new standard of care.
Dr. Frank Sinicrope, the Mayo Clinic oncologist who led the study, emphasizes that this represents a “major advance” and will “change clinical practice.” That change will ripple outwards, impacting not only oncologists but also gastroenterologists, genetic counselors, and primary care physicians throughout the Austin metropolitan area. The National Comprehensive Cancer Network (NCCN) has already updated its guidelines to include this treatment recommendation, further solidifying its place as the new standard.
Beyond Treatment: The Role of Prevention and Early Detection
While this new immunotherapy combination offers hope for those already diagnosed with stage 3 dMMR colon cancer, it’s crucial to remember the importance of prevention and early detection. Regular screenings, particularly for individuals over 45 (or earlier if there’s a family history of colorectal cancer or Lynch syndrome), remain the cornerstone of combating this disease. Organizations like the American Cancer Society and the Colon Cancer Coalition actively promote awareness and advocate for increased screening rates. Here in Austin, local initiatives focused on community outreach and education are vital to ensuring that everyone has access to the information and resources they require to protect their health.
Navigating the New Landscape: A Local Resource Guide
Given my background in health communications and a deep understanding of the complexities of cancer care, if this trend impacts you or a loved one in Austin, here are three types of local professionals you’ll want to consider consulting:
- Board-Certified Medical Oncologists: Look for oncologists affiliated with leading Austin hospitals (Dell Medical School, St. David’s, Ascension Seton) who specialize in colorectal cancer and have experience with immunotherapy treatments. Specifically, inquire about their experience with dMMR tumors and their familiarity with the latest NCCN guidelines.
- Certified Genetic Counselors: Understanding your genetic predisposition to colorectal cancer is paramount. A certified genetic counselor can assess your family history, order appropriate genetic testing, and assist you interpret the results. Seek counselors who are board-certified by the American Board of Genetic Counseling (ABGC) and have experience with Lynch syndrome.
- Registered Dietitians specializing in Oncology Nutrition: Nutrition plays a critical role in cancer treatment and recovery. A registered dietitian specializing in oncology nutrition can help you develop a personalized eating plan to support your immune system, manage treatment side effects, and optimize your overall health. Look for dietitians who are registered with the Commission on Dietetic Registration (CDR) and have specific training in oncology nutrition.
Ready to identify trusted professionals? Browse our complete directory of top-rated healthcare experts in the Austin area today.